Key clinical point: Sustained virologic response (SVR) decreases the risk for hepatic decompensation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) receiving nonsurgical treatment.
Major finding: Patients with SVR vs viremia had a significantly lower likelihood of hepatic decompensation (adjusted odds ratio 0.18; 95% CI 0.06-0.59).
Study details: Findings are from a multicenter, retrospective cohort study including adult patients with HCV cirrhosis and treatment-naive HCC who had active viremia (n = 431) or SVR before HCC diagnosis (n = 135).
Disclosures: This study was sponsored by the US National Institutes of Health. Some authors reported serving as consultants, advisory board members, speakers for, or receiving research funding or consulting fees from various sources.
Source: Parikh ND et al. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 (Jul 7). Doi: 10.1002/cncr.34378
